Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 Inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Antitumor Agent-Reference-Cited by-同舟云学术

Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 Inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Antitumor Agent

Published:2020-01-02 Issue:3 Volume:63 Page:1084-1104
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Kurasawa Osamu¹^ORCID,Miyazaki Tohru¹,Homma Misaki¹,Oguro Yuya¹,Imada Takashi¹,Uchiyama Noriko¹,Iwai Kenichi¹,Yamamoto Yukiko¹,Ohori Momoko¹,Hara Hideto¹,Sugimoto Hiroshi¹^ORCID,Iwata Kentaro²,Skene Robert³,Hoffman Isaac³,Ohashi Akihiro¹,Nomura Toshiyuki¹,Cho Nobuo¹

Affiliation:

1. Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan

2. Pharmaceutical Sciences, Takeda Pharmaceutical Company, Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan

3. Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01427

Reference24 articles.

1. Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication